[Market Focus] Samyang Biopharm Hits Upper Price Limit for Second Day After Spin-Off

Samyang Biopharm is hitting the upper price limit for the second consecutive day on November 25, its second day of trading after a spin-off and relisting.

As of 10:25 a.m. on this day, Samyang Biopharm is trading at 39,250 won, up 29.97% from the previous trading day. Following its spin-off from Samyang Holdings, the holding company of Samyang Group, and relisting the previous day, the stock has reached the upper limit for two consecutive days. The total number of Samyang Biopharm shares listed is 7,435,870.

Samyang Biopharm is an independent company dedicated to pharmaceutical and biotech businesses. Analysts attribute the surge in buying to heightened expectations that the spin-off and relisting will allow the company’s technological capabilities and growth potential to be more highly valued in the market. The company plans to strengthen its global competitiveness by focusing on high-performance bio products such as biodegradable surgical sutures, gene delivery systems, and anticancer drugs.